Anti-claudin-2 monoclonal antibody
An object of the present invention is to provide a monoclonal antibody that recognizes an extracellular region of Claudin-2. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2.
1. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2, the monoclonal antibody comprising:
the heavy-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 13 and the light-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 15;
and wherein the heavy-chain variable region comprising: heavy-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, heavy-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and heavy-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and wherein the light-chain variable region comprising: light-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, light-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and light-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
2. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody recognizes a three-dimensional structure of the extracellular region of Claudin-2.
3. The monoclonal antibody according to claim 1 , wherein the extracellular region is an extracellular region first loop of Claudin-2.
4. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody has a structure of Fab, Fab′, (Fab′) 2 , Fv, scFv, or a combination thereof.
5. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.
6. A pharmaceutical composition comprising the monoclonal antibody according to claim 1 .
7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is used for the treatment of inflammatory bowel disease.
8. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is used for the treatment of cancer.
9. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2, the monoclonal antibody comprising:
the heavy-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 14 and the light-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 16; and wherein the heavy-chain variable region comprising: heavy-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, heavy-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and heavy-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the light-chain variable region comprising: light-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8, light-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and light-chain CDR3 comprising the amino acid of SEQ ID NO: 12.
10. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody recognizes a three-dimensional structure of the extracellular region of Claudin-2.
11. The monoclonal antibody according to claim 9 , wherein the extracellular region is an extracellular region first loop of Claudin-2.
12. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody has a structure of Fab, Fab′, (Fab′) 2 , Fv, scFv, or a combination thereof.
13. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.
14. A pharmaceutical composition comprising the monoclonal antibody according to claim 9 .
15. The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition is used for the treatment of inflammatory bowel disease.
16. The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition is used for the treatment of cancer.